MedDataX Logo

Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling

NCT00132119 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2008-05-19

No results posted yet for this study

Summary

The purpose of this study is to determine if nalmefene is safe and effective in the treatment of pathological gambling.

Conditions

  • Pathological Gambling

Interventions

DRUG

nalmefene HCl

Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.

OTHER

Placebo

Placebo tablet

Sponsors & Collaborators

  • Somaxon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Philip Jochelson, MD · Somaxon Pharmaceuticals CMO

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2006-08-31
Completion
2006-08-31

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132119 on ClinicalTrials.gov